https://doi.org/10.1351/goldbook.13229
Genetically engineered monoclonal antibody of non-human origin in which all but the antigen-binding complementarity-determining region (CDR) sequences have been replaced with sequences derived from human antibodies.
Note: This procedure is carried out to minimize the immunogenicity of therapeutic, monoclonal antibodies.